CAR-T Clinical Trial
Official title:
Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
This is a phase I, single arm, non-randomized, open label, treatment study trial to determine the recommended phase II dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is a kind of autoimmune diseases mediated by autoantibody-forming immune complexes, which involving multiple systems and organs. Autoreactive B cells can self-activate and differentiate into plasma cells releasing large amounts of autoantibodies, while they can also present their own antigens to autoimmune T cells, thus activating T cells and promoting the release of inflammatory factors. Traditional SLE treatment aims at long-term remission, while, CD19- BCMA CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells, allowing immune rebuilding and restoring the patient's normal immune function, achieving drug-free survival, which fully reflects the application prospects of CAR-T therapy in SLE. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04691349 -
CAR-T for r/r Malignant Tumors in Children
|
Early Phase 1 | |
| Recruiting |
NCT05514327 -
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
|
N/A | |
| Recruiting |
NCT04203459 -
The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
|
||
| Recruiting |
NCT04048434 -
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
|
N/A | |
| Recruiting |
NCT01166009 -
CIBMTR Research Database
|
||
| Recruiting |
NCT06210243 -
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
|
Phase 1 |